Steve was appointed President and Chief Executive Officer and elected to the Board of Directors of Cambrex Corporation in May 2008. Cambrex, a NYSE listed life sciences company provides products and services to accelerate drug discovery, development and manufacturing processes for the pharmaceutical industry. The company employs over 850 employees and has FDA and EMEA regulated facilities in North America, Italy, and Sweden and an R&D center in Estonia and specializes in producing small molecule active pharmaceutical ingredients and advance intermediates for both branded and generic therapeutics.

Steve joined Cambrex in 1992 as Vice President for Administration and over the past 16 years has served as the Executive Vice President and Chief Operating Officer for the company’s biopharmaceutical and pharmaceutical divisions and as Chief Operating Officer for the corporation. During Steve’s tenure, Cambrex has grown from $100 million in sales to over half a billion and completed twelve strategic acquisitions in the US and Europe and transformed the company into a premier life sciences supplier with technology platforms including biologics, cell therapy and small molecules. In 2007, Cambrex sold its biologics and cell therapy businesses for $460 million and now is exclusively focused on small molecule therapeutics and drug delivery systems and generates global revenues of $250 million per year.

Prior to joining Cambrex, he served as Vice President, Administration & Corporate Secretary for The Genlyte Group, Inc., a leading provider of lighting systems and electronic controls. Steve was one of the corporate officers responsible for spinning off Genlyte into one of the largest public lighting companies in the industry. While working at Genlyte, he completed his law degree as an evening student.

Steve has a B.S. in Industrial & Labor Relations from Cornell and a J.D. from New York Law School. In addition to serving on the Board of Directors of Cambrex, Steve is a member of the Board of Trustees of the St. Joseph Hospital Foundation and NPS, a privately held plastics manufacturer. He looks forward to returning to Cornell to talk to both ILR and biomedical engineering students about his career path and Cambrex’s life sciences business.

At the time of the 35th reunion, Steve and Rena are delighted that the Klosk family Cornell tradition is being continued by their daughter, Julia '15, Dyson School. Steve continues as CEO of Cambrex which was recently featured in Investor’s Business Daily and is growing at double digit rates and has expanded with businesses in the US, Europe and India.

At the time of our 40th reunion, Steve and Rena recently moved to the Upper West Side of Manhattan and are delighted to be spending more time with their 3 children who live in NYC. Steve continues to run Cambrex and recently completed the acquisition of two large businesses adding to Cambrex’s global life sciences platform. He is also excited to be serving on the Board of Caladrius Biosciences, a leading cell therapy company.